Studio City International Holdings Limited (MSC) Stock

MSC Industrial Direct Co., Inc. MSM will release its first-quarter financial results, before the opening bell, on Wednesday, Jan. 8, 2025.

NEW YORK, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced the Food and Drug Administration (FDA) approved Ryoncil® (remestemcel-L) as the first mesenchymal stromal cell (MSC) therapy in the United States. RYONCIL is the only MSC therapy approved in the U.S. for any indication, and the only approved therapy for steroid-refractory acute graft versus host disease (SR-aGvHD) in children 2 months and older, including adolescents and teenagers.

MELVILLE, N.Y. and DAVIDSON, N.C.

MELVILLE, N.Y. and DAVIDSON, N.C.

MELVILLE, N.Y. and DAVIDSON, N.C.

FISCAL 2024 Q4 HIGHLIGHTS Net sales of $952.3 million decreased 8.0% YoY and includes a roughly 300 basis point headwind from non-repeating Public Sector orders in the prior year Operating income of $90.9 million, or $94.2 million adjusted to exclude acquisition-related and restructuring and other costs1 Operating margin of 9.5%, or 9.9% excluding the adjustments described above1 Diluted EPS of $0.99 vs. $1.56 in the prior fiscal year quarter Adjusted diluted EPS of $1.03 vs.

MSM's latest dividend hike takes its dividend yield from 4.00% to 4.10%.

MELVILLE, N.Y. and DAVIDSON, N.C.

Martina McIsaac to assume responsibility of MSC's day-to-day operations Erik Gershwind to sharpen focus on MSC's strategy, growth planning and organizational development MELVILLE, N.Y. and DAVIDSON, N.C.